Proparacaine
- Generic Name
- Proparacaine
- Brand Names
- Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C16H26N2O3
- CAS Number
- 499-67-2
- Unique Ingredient Identifier
- B4OB0JHI1X
- Background
Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.
- Indication
Used as a local (ophthalmic) anesthetic.
- Associated Conditions
- Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)
- Associated Therapies
- Local Anaesthesia therapy
Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2010-07-26
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 226
- Registration Number
- NCT01169337
- Locations
- 🇺🇸
Illinois CancerCare-Carthage, Carthage, Illinois, United States
🇺🇸Memorial Hospital, Carthage, Illinois, United States
🇺🇸Centralia Oncology Clinic, Centralia, Illinois, United States
A Phase I, Multicenter, Open-label, Dose-escalation Study to Assess the Safety of Lenalidomide in Patients With Advanced Adult T-cell Leukemia-lymphoma and Peripheral T-cell Lymphomaperipheral T-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2010-07-26
- Last Posted Date
- 2019-11-08
- Lead Sponsor
- Celgene
- Target Recruit Count
- 13
- Registration Number
- NCT01169298
- Locations
- 🇯🇵
Imamura Bun-in Hospital, Kagoshima, Japan
🇯🇵Nagoya Daini Red Cross Hospital, Nagoya, Japan
🇯🇵Kumamoto University Hospital, Kumamoto, Japan
Lenalidomide and Cetuximab in Patients With Advanced Solid Tumors
- Conditions
- First Posted Date
- 2010-07-20
- Last Posted Date
- 2010-07-20
- Lead Sponsor
- Medical University Innsbruck
- Target Recruit Count
- 20
- Registration Number
- NCT01166035
- Locations
- 🇦🇹
Medical University of Innsbruck, Department for Internal Medicine I, Innsbruck, Tyrol, Austria
Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2010-07-02
- Last Posted Date
- 2020-11-16
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 45
- Registration Number
- NCT01155583
- Locations
- 🇺🇸
University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
🇺🇸Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Lenalidomide and Rituximab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma
- Conditions
- Ann Arbor Stage II Grade 3 Contiguous Follicular LymphomaAnn Arbor Stage III Grade 1 Follicular LymphomaAnn Arbor Stage IV Grade 2 Follicular LymphomaAnn Arbor Stage IV Grade 3 Follicular LymphomaAnn Arbor Stage IV Grade 1 Follicular LymphomaAnn Arbor Stage II Grade 2 Contiguous Follicular LymphomaAnn Arbor Stage II Grade 2 Non-Contiguous Follicular LymphomaAnn Arbor Stage II Grade 3 Non-Contiguous Follicular LymphomaAnn Arbor Stage III Grade 3 Follicular LymphomaAnn Arbor Stage II Grade 1 Contiguous Follicular Lymphoma
- Interventions
- First Posted Date
- 2010-06-16
- Last Posted Date
- 2023-06-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 66
- Registration Number
- NCT01145495
- Locations
- 🇺🇸
Memorial Hospital, Carthage, Illinois, United States
🇺🇸Illinois CancerCare-Havana, Havana, Illinois, United States
🇺🇸Heartland Cancer Research NCORP, Decatur, Illinois, United States
Lenalidomide and Prednisone in Low and Int-1 Myelodysplastic Syndrome (MDS) Non 5q MDS
- Conditions
- Interventions
- First Posted Date
- 2010-05-28
- Last Posted Date
- 2019-12-17
- Target Recruit Count
- 28
- Registration Number
- NCT01133275
- Locations
- 🇺🇸
University of Florida Shands Cancer Center, Gainesville, Florida, United States
🇺🇸H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia
- Conditions
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAdult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARASecondary Myelodysplastic SyndromeAdult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11de Novo Myelodysplastic SyndromeAdult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLLAlkylating Agent-Related Acute Myeloid LeukemiaPreviously Treated Myelodysplastic SyndromeRecurrent Adult Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2010-05-28
- Last Posted Date
- 2014-12-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 61
- Registration Number
- NCT01132586
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Open-label Pilot Study of Lenalidomide (Revlimid) as Adjuvant Treatment for Refractory Cutaneous T Cell Lymphoma
- Conditions
- First Posted Date
- 2010-05-28
- Last Posted Date
- 2010-05-28
- Lead Sponsor
- Florida Academic Dermatology Centers
- Target Recruit Count
- 10
- Registration Number
- NCT01132989
- Locations
- 🇺🇸
Florida Academic Dermatology Center, Miami, Florida, United States
RESPeCT: Revlimid Early Stage Poor Prognosis Chronic Lymphocytic Leukaemia (CLL) Trial
- First Posted Date
- 2010-05-21
- Last Posted Date
- 2011-12-05
- Lead Sponsor
- The Christie NHS Foundation Trust
- Target Recruit Count
- 1
- Registration Number
- NCT01127542
- Locations
- 🇬🇧
The Royal Bournemouth Hospital, Bournemouth, Dorset, United Kingdom
🇬🇧St James's University Hospital, Leeds, United Kingdom
🇬🇧Addenbrooke's Hospital, Cambridge, United Kingdom
Lenalidomide for Lean Body Mass and Muscle Strength in Inflammatory Cancer Cachexia Syndrome
- Conditions
- Interventions
- First Posted Date
- 2010-05-20
- Last Posted Date
- 2017-08-01
- Lead Sponsor
- Florian Strasser, MD ABHPM
- Target Recruit Count
- 200
- Registration Number
- NCT01127386
- Locations
- 🇨🇭
Kantonsspital St.Gallen, St.Gallen, Switzerland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.